Literature DB >> 23206844

Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation.

Jean-Philippe Bastien1, Jean Roy, Denis Claude Roy.   

Abstract

Haplotype-mismatched transplantation offers a unique opportunity to treat patients without a suitable matched related or unrelated donor. Indeed, related haplo-donors are usually extremely motivated, immediately available, and can provide additional stem or immune cells when required, a most important feature in the context of high-risk malignancies. Immunomagneticallly selected CD34(+) stem cell grafts enable rapid and sustained trilineage engraftment. However, the associated delay in immune reconstitution results in significant risk for severe infectious complications and malignant relapse. The infusion of T lymphocytes selectively depleted of their anti-host reactive components represents a most interesting approach to accelerate post-transplant T-cell recovery. Such a strategy relies on ex vivo donor cell activation against host antigens and their selective elimination. Immunotoxins and magnetic beads could target antigens such as CD25 with impressive results. Photodepletion of alloreactive T cells represents an appealing alternative to both eliminate anti-host immune T cells and spare resting T cells to fight infections. Interestingly, regulatory T cells can be retained after such treatment, and have been found to transform non-regulatory into regulatory T cells, a finding that may be of utmost importance in both prevention and control of graft-versus-host disease (GVHD). Efforts to promote efficient antigen presentation and selective allodepletion promise to accelerate immune reconstitution without GVHD and to address the most crucial issues in haplo-mismatched and other types of transplants.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23206844     DOI: 10.1053/j.seminoncol.2012.09.004

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  20 in total

1.  Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts.

Authors:  K Mizrahi; I Yaniv; S Ash; J Stein; N Askenasy
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

2.  Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.

Authors:  Alessandra Roberto; Luca Castagna; Veronica Zanon; Stefania Bramanti; Roberto Crocchiolo; James E McLaren; Sara Gandolfi; Paolo Tentorio; Barbara Sarina; Inna Timofeeva; Armando Santoro; Carmelo Carlo-Stella; Benedetto Bruno; Cristiana Carniti; Paolo Corradini; Emma Gostick; Kristin Ladell; David A Price; Mario Roederer; Domenico Mavilio; Enrico Lugli
Journal:  Blood       Date:  2015-03-05       Impact factor: 22.113

3.  Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Authors:  Shannon R McCurdy; Jennifer A Kanakry; Margaret M Showel; Hua-Ling Tsai; Javier Bolaños-Meade; Gary L Rosner; Christopher G Kanakry; Karlo Perica; Heather J Symons; Robert A Brodsky; Douglas E Gladstone; Carol Ann Huff; Keith W Pratz; Gabrielle T Prince; Amy E Dezern; Ivana Gojo; William H Matsui; Ivan Borrello; Michael A McDevitt; Lode J Swinnen; B Douglas Smith; Mark J Levis; Richard F Ambinder; Leo Luznik; Richard J Jones; Ephraim J Fuchs; Yvette L Kasamon
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

Review 4.  Haploidentical hematopoietic stem cell transplantation: state of art.

Authors:  Y Reisner; F Aversa; M F Martelli
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 5.  Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies.

Authors:  Michael J Ricci; Jeffrey A Medin; Ronan S Foley
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

6.  Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.

Authors:  Greg D Whitehill; Shoba Amarnath; Pawel Muranski; Keyvan Keyvanfar; Minoo Battiwalla; Austin J Barrett; Dhanalakshmi Chinnassamy
Journal:  Mol Ther       Date:  2016-07-06       Impact factor: 11.454

Review 7.  Graft versus tumor effects and why people relapse.

Authors:  J H Frederik Falkenburg; Inge Jedema
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD.

Authors:  Y Zeng; J Stokes; S Hahn; E Hoffman; E Katsanis
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

Review 9.  Allo-reactive T cells for the treatment of hematological malignancies.

Authors:  J H F Falkenburg; I Jedema
Journal:  Mol Oncol       Date:  2015-10-24       Impact factor: 6.603

Review 10.  Mechanistic approaches for the prevention and treatment of chronic GVHD.

Authors:  Corey S Cutler; John Koreth; Jerome Ritz
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.